title: Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia.
abstract: Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.
authors.affiliation: Department of Hematology and Oncology, Robert Lurie Cancer Center and Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA . strifili@nmh.org
authors.forename: Steven
authors.initials: S
authors.lastname: Trifilio
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhou
authors.forename: Jessica
authors.initials: J
authors.lastname: Altman
authors.forename: Olga
authors.initials: O
authors.lastname: Frankfurt
authors.forename: Mihaela
authors.initials: M
authors.lastname: Pantiru
authors.forename: Jayesh
authors.initials: J
authors.lastname: Mehta
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D020732:Cytogenetic Analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D016879:Salvage Therapy / Q000379:methods; D016019:Survival Analysis
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide